4th European Innovation Summit
Event Type
Organiser type
Section
Event Location
Event Description
Knowledge4Innovation will be organising the 4th European Innovation Summit from 9 to 10 October 2012 in the European Parliament in Brussels.
Under the motto “Building bridges – Creating Synergies”, this year’s debates relate to policies relevant for innovation and that are currently under review by the European Parliament, including Horizon2020, Cohesion Policy, COSME and the MFF. The summit features an opening reception with Innovation Commissioner Geoghegan-Quinn, several thematic sessions throughout two days, breakfasts, lunches and dinner debates, as well as an exhibition in one of the most visible locations of the European Parliament. In addition, the “Innovative Europe Reality Check” provides an opportunity for innovation practitioners to describe online their major challenges and express ideas on how to improve the framework conditions for innovation.
Related Events
Securing Europe‘s Raw Material Supply in the Context of Resource Efficiency and EU Industry Policy
There is no energy- and resource efficiency, no climate protection, no future technologies for our modern
world without the use of non-ferrous metals.
Monday 5 November 2012 (day 1)
15:00-16:30: European Parliament Briefing (optional): Enterprise Forum members will have the opportunity to attend a briefing on how the European Parliament works. Paul-Henri Spaak Building, Rue Wiertz, B-1047 Brussels
SMEs are the backbone of the European economy. Of the approximately 20 million SMEs in Europe, one third is active in the field of commerce.
COST will be a partner of the fourth European Innovation Summit to be held at the European Parliament in Brussels under the motto 'Building bridges – Creating Synergies'.
An existing literature agrees that drug innovation has a significant average effect on extending longevity and improving quality of life. Recognizing the life-saving benefits from the development of new drugs, one of the key decisions faced by the authorities is how to bolster pharmaceutical innovation, and how to bear in mind the potential effects on drug innovation of policies that affect market size, such as policies towards intellectual property rights, procurement mechanisms and competition policy.
Pages
Events of the week
Jobs
EURACTIV News
- Israel strikes multiple Houthi targets in Yemen
- ‘Agenda 2030’ or stagnation: Germany faces Schröder moment in 2025
- Tough energy poker in eastern Mediterranean after Assad’s fall in Syria
- Putin says Slovakia could host peace talks with Ukraine
- Finland boards oil tanker suspected of causing internet, power cable outages